June 14, 2012 — A U.S. Food and Drug Administration (FDA) advisory panel voted in favor of recommending expanding the indication for the Edwards Lifesciences Sapien transcatheter heart valve for the treatment of high-risk patients. Currently, the Sapien is only indicated for patients who are too sick to undergo valve replacement surgery for severe, symptomatic aortic stenosis. The panel voted 11-0, with one abstention, that the benefits of the heart valve outweighed the risks for these patients.

As the nation’s leading provider of maternal-fetal, newborn and pediatric subspecialty physician services, Pediatrix Medical Group says streamlining the transfer of images and reports is a priority. Seeking a faster, more reliable method of exchanging files than on CD, the group adopted a cloud-based medical information exchange.